Pharma Mar (OTCMKTS:PHMMF) Shares Gap Up - Here's Why

Key Points

• Shares gapped up before the open, rising from $96.00 to an open of $106.15 and last trading around $106.48, up about 5.8% on volume of 10,300 shares.
• Price is trading above the 50‑day ($91.65) and 200‑day ($91.10) moving averages, and the company shows strong liquidity (current ratio 3.02, quick ratio 2.44) with a low debt‑to‑equity ratio of 0.14.
• PharmaMar is a Spain‑based biopharmaceutical focused on marine‑derived oncology therapies; its flagship product Yondelis (trabectedin) is approved in the EU for soft tissue sarcoma and relapsed platinum‑sensitive ovarian cancer.

Shares of Pharma Mar (OTCMKTS:PHMMF - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $96.00, but opened at $106.15. Pharma Mar shares last traded at $106.4775, with a volume of 10,300 shares.

Pharma Mar Trading Up 5.8%

The business's fifty day moving average is $91.65 and its 200 day moving average is $91.10. The company has a current ratio of 3.02, a quick ratio of 2.44 and a debt-to-equity ratio of 0.14.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company's flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.